LLY vs OSCR

Eli Lilly exhibits a stark divergence between explosive growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company delivers exceptional ROE (101.16%) and massive YoY revenue growth (42.6%), it trades at a significant premium to both its Graham Number ($123.85) and growth-based intrinsic value ($678.2). The current valuation is driven by high expectations for its drug pipeline, but the low deterministic health score and bearish technical trend suggest a period of consolidation or risk. Overall, it is a high-performance growth engine with concerning balance sheet efficiency metrics.

Oscar Health exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company maintains a low Price-to-Sales ratio (0.48) and steady revenue growth of 17.3%, it continues to struggle with negative profit margins and a consistent failure to meet earnings estimates (0/4 beats in the last year). The recent 60.9% one-month price surge appears disconnected from fundamentals, as the stock now trades above the analyst target price of $16.10. Combined with aggressive insider selling by the CFO and CTO, the risk-reward profile is unfavorable.